MDCX MDCX
Company Profile ↓Company Overview
MDCX (MDCX) is a publicly traded company listed on with a market capitalization of $7.55M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -87.53% |
| 6 Months: | -75.27% |
| 3 Months: | +7.93% |
| 1 Month: | -32.55% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 89.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -1.71M | -3.55M | -2.33M | -5.13M | -6.02M | -15 | -8.60M |
| Net Income | -1.71M | - | -2.28M | -5.10M | - | -20.94M | -9.04M |
| Diluted EPS | -0.21 | -0.44 | -0.24 | -0.42 | -0.43 | -1.12 | -0.31 |
| R&D Expense | 321.38K | 1.28M | 564.14K | 2.01M | 1.44M | 1.68M | 2.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -4.73M | -11.18M | -34.36M |
| Net Income | -5.31M | -11.16M | -47.28M |
| Diluted EPS | -1.53 | -1.16 | -2.74 |
| R&D Expense | 193.58K | 3.53M | 7.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 282.65K | 1.89M | 5.65M | 10.06M |
| Current Assets | - | 282.65K | 1.89M | 5.38M | 9.89M |
| Cash & Equivalents | - | 267.65K | 1.72M | 4.16M | 8.71M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 12.48M | 781.61K | 2.51M | 10.02M |
| Current Liabilities | - | 12.48M | 781.61K | 2.31M | 9.94M |
| Long Term Debt | - | - | - | - | 25.86K |
| Total Debt | - | 1.53M | 0 | 322.27K | 5.48M |
| Total Equity | - | -12.20M | 1.11M | 3.13M | -67.55K |
| Shares Outstanding | - | 8.05M | 8.08M | 11.82M | 25.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -4.16M | -10.25M | -22.78M |
| Investing Cash Flow | - | 0 | -4.62M |
| Financing Cash Flow | 5.61M | 12.69M | 31.94M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -478.2% | -355.9% | 69,990.7% |
| ROCE % | -425.6% | -334.7% | -27,863.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDCX
Medicus' chief medical officer is set to lead its UK subsidiary Aug. 30 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNTlhCY2dYbE5CMVhuTExyUFROY0QxX2FIcU5TWEx2dUhJanZQMW1hWlNGWDdySnNIdFZzMjNQenV6S2dYbFgtYXVVbVIyQ3FYZHRwU3hCd202WGgwRGQwM2hUejM2ME9VcVhFU2dtSnBlQWVFRWZlckNjRlF6c1MzN0ZLandHOC1xWXhyVn…
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNTHh3T2hxWWVrcmEwd0xBS1QyWFBuenJ0aFh0ajh6RVE0WnVQbWFEUU9lbEtoS2lHODVYZEttcmlMM0EzU0N5dEtCMS1EYWNjLUNtUkJ6Nnd6MXNPLVlvNjFKeU9DcDRWRHI0N09OMU5sUVg0ME1Wd1B4MVVSSVFnUGlJRVo4VTc0d0FaNz…
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCX - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1hTmNvZS0xWE9JRUJNUmg2V1FheVJDRUFyRWI1cUw1UVh4SE5SZi1FcWwtYmVQemMtbWdyNjU5YW5EUlpCUTFYcXJpV3RYX3FXSGxOcUtfM0h4UkpjNml2YnJFVlNOLUtoeFA1Wk9ZQUFQdElCal9F?oc=5" target="_blank">Medicus…
Medicus Pharma Appoints New CEO to Drive Development - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNMGpLaFdjeXI0TUlqX1IyYUttbkIwQVRtd05Qek5TZDhGVzBYRXU4VmZuOUhqWFZHLTVuQ1dEWXNRaV9mU3JPdHR5M081N2d3MHlmeHAxOTBOTC1jXzR5VmtUTFFGYmZLeWY2N2pCbWtpekRtM0xMS2EzNmN3YkNySlR1M29OdXBydTNFSF…
Medicus Pharma (NASDAQ:MDCX) Share Price | RNS News, Quotes, & Charts | MDCX | - Proactive Investors
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE5ERUdzWEYwRGtYLTVxYnhENVE0ZldFQTRkNWZTTmVTYVgya2xVNDllNGRtZ3d3LUp1anJhZ2hXNDVON0RRVXQwaEUzYTl6ZFIwTXRUU0hENDRXc2tlNGNaMVVRQlJieF96ajl2NWIyR2Q?oc=5" target="_blank">Medicus Pharma (…
About 84 Women, Four Groups: Teverelix Endometriosis Trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPVWRWTVJUekZwQ3ktdzJtRWRVNDVqREJlYUltdjVLUFpiSDkzYks2YWwtNVpaNUFfSGtfQ2RQeUhidUNIMjNabVlWTUVWVWxHdFl2VW1kNGQ3UHN6SDFHV0N2RjBqSTVGek1vY1lzeFg0Uy1UOE9lYmRKR2ZPUDhweHJndzUtdFNoQ0I3V3…
MDCX — Frequently Asked Questions
What is the current share price of MDCX?
As of 2026-08-05 17:25 PDT, MDCX trades at $0.30 on NASDAQ/NYSE. Its 52-week range is $0.26 to $2.80.
What is the market capitalisation of MDCX?
MDCX has a market capitalisation of $7.55M on NASDAQ/NYSE.
What is the P/E ratio of MDCX?
MDCX trades at a trailing price-to-earnings (P/E) ratio of -0.11. Its price-to-book (P/B) ratio is -111.11.
Is MDCX a good stock to buy?
This page provides a data-driven analysis of MDCX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.